Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial.

Seef AbdallaAlexandra CompagnucciYi ZhengJean-Marc TréluyerYacine SaidiJosé T RamosAlexandra CoelhoYoann RiaultTim R CresseyDéborah Hirtnull null

Published in: The Journal of antimicrobial chemotherapy (2023)

A once-daily 50 mg dolutegravir dose for children and adolescents produces adequate total and unbound concentrations when used as part of dual therapy with ritonavir-boosted darunavir.

Keyphrases

hiv infected patients
antiretroviral therapy
physical activity
young adults
study protocol
clinical trial
phase iii
phase ii
middle aged
community dwelling
stem cells